menu
    • menu

    Company profile for Nurix Therapeutics

    NEW Drugs in Dev: 8
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach called targeted protein modulation to treat a broad range of diseases. Our focus is on developing targeted therapies to treat cancer including novel, small molecule immuno-oncology agents...
    Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach called targeted protein modulation to treat a broad range of diseases. Our focus is on developing targeted therapies to treat cancer including novel, small molecule immuno-oncology agents. Nurix was founded by a team of internationally renowned scientific experts in the E3 ubiquitin ligase regulation and structure field

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nurix TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1700 Owens Street, Suite 205 San Francisco, CA 94158
    Telephone
    Telephone
    415-660-5320
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nurixtx.com/contact/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nurix Reports Updated Phase 1a/b Bexobrutideg Data in CLL/SLL
    Nurix Reports Updated Phase 1a/b Bexobrutideg Data in CLL/SLL

    11 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/11/3310331/0/en/nurix-therapeutics-to-report-updated-phase-1a-b-results-for-btk-degrader-bexobrutideg-highlighting-durable-responses-in-relapsed-refractory-cll-sll-and-promising-activity-in-earlie.html

    GLOBENEWSWIRE
    11 Jun 2026
    Share Share
    Roche Invests $3B In Nurix's Blood Cancer Protein Degrader
    Roche Invests $3B In Nurix's Blood Cancer Protein Degrader

    08 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/08/3307778/0/en/roche-announces-global-collaboration-with-nurix-therapeutics-to-co-develop-and-co-commercialise-potential-best-in-class-btk-degrader-bexobrutideg-across-malignant-haematology-immun.html

    GLOBENEWSWIRE
    08 Jun 2026
    Share Share
    Nurix Presents Bexobrutideg Phase 1 Data at SID 2026
    Nurix Presents Bexobrutideg Phase 1 Data at SID 2026

    14 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/14/3295365/0/en/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-de.html

    GLOBENEWSWIRE
    14 May 2026
    Share Share
    Nurix Therapeutics Joins Investor Conferences
    Nurix Therapeutics Joins Investor Conferences

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293827/0/en/nurix-therapeutics-to-participate-in-upcoming-investor-conferences.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Nurix Therapeutics Presents Bexobrutideg At 2026 EHA Congress
    Nurix Therapeutics Presents Bexobrutideg At 2026 EHA Congress

    12 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/12/3293370/0/en/nurix-therapeutics-announces-bexobrutideg-oral-presentation-at-the-2026-european-hematology-association-congress.html

    GLOBENEWSWIRE
    12 May 2026
    Share Share
    Nurix Presents Protein Degradation Pipeline Data at AACR 2026
    Nurix Presents Protein Degradation Pipeline Data at AACR 2026

    22 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/22/3278794/0/en/nurix-therapeutics-announces-new-preclinical-data-highlighting-breadth-of-targeted-protein-degradation-pipeline-at-aacr-2026.html

    GLOBENEWSWIRE
    22 Apr 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search